Form 4: BioSig Technologies CEO Acquires Shares in Lieu of Cash Compensation

Anthony N. Amato, CEO of BioSig Technologies, acquired 23,345 shares of common stock in lieu of cash for Q4 2024 and Q1 2025 board fees.

Summary

• On April 24, 2025, Anthony N. Amato, the CEO of BioSig Technologies, acquired 23,345 shares of the company's common stock.
• These shares were granted under the company's 2023 Equity Incentive Plan.
• The shares were issued in lieu of cash compensation for Q4 2024 and Q1 2025 board fees.
• The shares were fully vested as of the date of grant, April 24, 2025.
• The closing price of BioSig Technologies' stock on the date of grant was $0.84 per share.
• Following the transaction, Amato directly owns 2,131,547 shares of BioSig Technologies.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a transaction where the CEO received stock in lieu of cash, which is a fairly standard practice. There's no indication of positive or negative implications.

Positives

• The CEO's acceptance of shares in lieu of cash may be viewed positively as it conserves company cash resources.
• The CEO's increased equity stake aligns his interests with those of other shareholders.

Industry Context

This type of equity compensation is common in the biotech industry, especially for smaller companies looking to conserve cash. It aligns management's interests with shareholders and incentivizes long-term growth.

Comparison to Industry Standards

• Granting stock options or restricted stock units (RSUs) in lieu of cash compensation is a common practice among small-cap and growth-stage companies, particularly in the biotech and technology sectors.
• Companies like Novavax and Sorrento Therapeutics have used similar strategies to manage cash flow and align executive incentives with shareholder value.
• The amount of equity granted in lieu of cash compensation varies widely depending on the company's size, stage of development, and overall compensation strategy.
• The vesting schedule and performance metrics associated with these grants also differ significantly across companies.

Stakeholder Impact

• Shareholders may view the acceptance of stock in lieu of cash as a positive sign, indicating the CEO's confidence in the company's future and helping to preserve cash resources.
• Employees may see this as a sign of financial prudence.

Key Dates

Keywords

BioSig Technologies, BSGM, Anthony Amato, CEO, stock acquisition, equity incentive plan, Form 4, beneficial ownership, board fees, compensation